Patrick Campbell

A survey of more than 3000 US physicians is shedding light on the impact of taking vacation time and avoiding physician-related work on vacation can have on burnout and achieving professional fulfillment.

A study of more than 140 adults with diabetes is providing additional insight into the prevalence of anemia among these patients as well as its association with changes in glycemic control.

Applied Therapeutics announced topline results from ARISE-HF on January 04, 2023 and plans to present full results at an upcoming medical conference.

Our endocrinology month in review spotlights our most popular content from December 2023. Our list of the most popular content from the past month includes the ADA Standards of Care—2024, label updates, a feature from our This Year in Medicine series, and more!

Our cardiology month in review spotlights our most popular cardiology-centric content from the month of December 2023. The list includes topline data from SEQUOIA-HCM, new data on the impact of structural racism on chronic health conditions, and more!

Post hoc analysis of STRONG-HF trial underscores benefits of higher guideline-directed medical therapy doses in acute heart failure, showing lower rates of death or readmission at 6 months with more rapid uptitration.

On December 27, 2023, Cytokinetics announced positive topline results from the phase 3 SEQUOIA-HCM trial evaluating aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy

Study raises concerns about quality of care in the future, as results reveal private equity takeovers of hospitals associated with increased hospital-acquired adverse events, including falls and infections.

The FDA has approved eplontersen (Wainua) for treating polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis, making it the only medication approved for self-administration via auto-injector pen for this condition.

A new study is raising awareness around the effects of structural racism on the prevalence of chronic health conditions.

Sex-based differences in hypertrophic cardiomyopathy outcomes reveal higher risks for women, including all-cause mortality.

Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

New data highlights the need for improved communication and understanding of barriers is evident for the effective management of type 2 diabetes.

Among adults in middle- to high-income nations, awareness of diabetes as a cardiovascular risk factor remains a persistent issue.

Results of the phase 2 RISE UP trial offer additional perspective into the benefit-risk profile of mitapivat in patients with sickle cell disease.

Bezuclastinib, a targeted oral therapy, shows promise in reducing disease burden and improving symptoms by 50% or more in nonadvanced systemic mastocytosis patients, as revealed in the phase 2 SUMMIT trial data presented at ASH 2023.

A substudy of the ASCEND trial offers insight into the effects of omega-3 fatty acids use on risk of diabetic retinopathy in people with diabetes.

A systematic review and meta-analysis provides insight into the potential for increased risk of noninfectious uveitis among people with vitamin D deficiency.

A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.

An overview of the journey and significant events of 2023 that have catapulted semaglutide from a type 2 diabetes agent to the topic of discussions among circles across healthcare and beyond.

Just more than a month after the FDA approved their first biosimilar to ustekinumab (Stelara), Bio-Thera Solutions announced positive results from their phase 3 trial of BAT2206

Announced on December 04, 2023, the approved label changes allow for administration regardless of timing of proton pump administration and for administration 15 minutes before breakfast.

Our November 2023 month in review for cardiology features highlights from AHA 2023, new atrial fibrillation guidelines, a pair of historic approvals from the FDA, and more!

A meta-analysis of trials examining use of preoperative iron infusions suggests use could reduce need for blood transfusions by 33% among patients undergoing colorectal surgery.

Released on Nov. 30, 2023, the new AFib guidance from the ACC/AHA contains update recommendations for early and aggressive rhythm control, wearables, left atrial appendage occlusion, and more.

A trial randomizing brain-dead donor hearts to levothyroxine administration or saline has returned results challenging conventional wisdom on the topic, with data indicating thyroid hormone administration may provide no significant benefit.

Data from a phase 3 trial of CT-P43 in patients with moderate to severe plaque psoriasis offers additional insight into the comparative effects of the biosimilar relative to ustekinumab.

An analysis of data from the Veterans Health Administration provides insight into disparities in the rates of endoscopy or colonoscopy among patients with iron deficiency anemia or hematochezia.

Results of the COMPACT study detail persistence rates, QoL data, and efficacy of biosimilar etanercept among patients in real-world settings.